TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35656977

Group type: COMPARATOR
Intervention: Lowest tertile of visit-to-visit systolic blood pressure (SBP) variability (SD)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Middle tertile of visit-to-visit SBP variability (SD)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Highest tertile of visit-to-visit SBP variability (SD)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Each 5-mm Hg increase in visit-to-visit SBP variability (SD)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Middle tertile of SBP variability (coefficient of variation)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Highest tertile of SBP variability (coefficient of variation)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Middle tertile of SBP variability (variation independent of the mean)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Highest tertile of SBP variability (variation independent of the mean)
Number of subjects: 1575
Study: 35656982

Group type: EXPERIMENTAL
Intervention: Low pre-PCI pullback pressure gradient (PPG)
Number of subjects: 1685

Group type: COMPARATOR
Intervention: High pre-PCI pullback pressure gradient (PPG)
Number of subjects: 1685
Study: 35657008

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35657082

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight loss)
Number of subjects: 139
Study: 35657428

Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled fibroblast activation protein inhibitor PET
Number of subjects: 0
Study: 35657429

Group type: EXPERIMENTAL
Intervention: Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 35657529

Group type: EXPERIMENTAL
Intervention: Neuro-functional disability at 12 months after CABM
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Functional disability at 12 months
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Physical disability at 12 months
Number of subjects: 281

Group type: COMPARATOR
Intervention: Dexamethasone use
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Pneumococcal meningitis
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Physical disability at hospital discharge
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Behavioral disorders at hospital discharge
Number of subjects: 281
Study: 35657564

Group type: EXPERIMENTAL
Intervention: Bundled intervention including an electronic health record (EHR) portal-based conversation guide, EHR clinical decision support (CDS), and self-management educational materials.
Number of subjects: 32
Study: 35657653

Group type: EXPERIMENTAL
Intervention: PF-06747775 monotherapy at recommended Phase 2 dose (200 mg QD)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PF-06747775 200 mg QD plus palbociclib (100 mg QD orally)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort
Number of subjects: 65
Study: 35657674

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Online discussion forum (ODF)
Number of subjects: 144
Study: 35657979

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Pembrolizumab+chemotherapy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 306
Study: 35658005

Group type: EXPERIMENTAL
Intervention: Adagrasib (600 mg orally twice daily)
Number of subjects: 116
Study: 35658021

Group type: EXPERIMENTAL
Intervention: Experiences of bullying in school
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Sense of belonging
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Being non-binary and being a transgender man
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Intention to enter a STEM field
Number of subjects: 539

Group type: COMPARATOR
Intervention: General sample comparison
Number of subjects: 539
Study: 35658469

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion after lymphodepletion
Number of subjects: 97
Study: 35658518

Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥25.0 kg/m²)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Nonobese group (BMI <25.0 kg/m²)
Number of subjects: 1227
Study: 35658525

Group type: EXPERIMENTAL
Intervention: KTE-X19 (2 × 10^6 cells/kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 68
Study: 35658861

Group type: EXPERIMENTAL
Intervention: BMI trajectory from stable normal to overweight
Number of subjects: 138110

Group type: EXPERIMENTAL
Intervention: BMI trajectory from stable normal to obese
Number of subjects: 138110

Group type: EXPERIMENTAL
Intervention: BMI trajectory from overweight to obese
Number of subjects: 138110

Group type: COMPARATOR
Intervention: Stable normal BMI
Number of subjects: 138110
Study: 35658916

Group type: EXPERIMENTAL
Intervention: Personal and domestic hygiene intervention including educational discussions and a brochure on lead exposure.
Number of subjects: 0
Study: 35659156

Group type: EXPERIMENTAL
Intervention: Culturally competent care intervention
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Initiated modifications by transplant team
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Individual versus institutional modifications
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CFIR inner setting factors
Number of subjects: 57
Study: 35659259

Group type: EXPERIMENTAL
Intervention: At-home modular brain-computer interface (BCI) platform
Number of subjects: 1
Study: 35659282

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (TCZ) 7 mg/kg Q4W
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (TCZ) 6 mg/kg Q4W
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous tocilizumab (TCZ) 8 mg/kg Q4W (previous treatment)
Number of subjects: 24
Study: 35659391

Group type: EXPERIMENTAL
Intervention: Hybrid machine learning-based algorithm combining hierarchical agglomerative clustering analysis and permutation feature importance method.
Number of subjects: 0
Study: 35659479

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) and a PD-1 inhibitor
Number of subjects: 0
Study: 35659581

Group type: EXPERIMENTAL
Intervention: Limertinib 160 mg orally twice daily
Number of subjects: 301
Study: 35660135

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study: 35660139

Group type: COMPARATOR
Intervention: Omicron phase (Dec 15, 2021, to Jan 31, 2022)
Number of subjects: 3473

Group type: COMPARATOR
Intervention: Unvaccinated patients during omicron phase
Number of subjects: 3473
Study: 35660542

Group type: EXPERIMENTAL
Intervention: Mayo-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545

Group type: COMPARATOR
Intervention: Cockcroft-Gault-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545

Group type: COMPARATOR
Intervention: C-MDRD-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545

Group type: COMPARATOR
Intervention: CKD-EPI-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545
Study: 35660797

Group type: EXPERIMENTAL
Intervention: Dostarlimab (anti-PD-1 monoclonal antibody), administered every 3 weeks for 6 months
Number of subjects: 12
Study: 35660920

Group type: EXPERIMENTAL
Intervention: Higher plasma phylloquinone concentrations (tertile 2-3)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Lower plasma phylloquinone concentrations with higher BMI
Number of subjects: 1208
Study: 35661166

Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg weekly after step-up doses of 0.06 mg and 0.3 mg per kg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Common adverse events
Number of subjects: 165
Study: 35661239

Group type: EXPERIMENTAL
Intervention: Prolonged QTc greater than 450 ms in infants with sensorineural hearing loss
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal QTc intervals in infants with sensorineural hearing loss
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Genetic testing for long QT syndrome
Number of subjects: 40
Study: 35661809

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35661896

Group type: EXPERIMENTAL
Intervention: Prolonged running (98.8 ± 14.7 min, 21.2 ± 3.8 km, 4.7 ± 0.3 min/km)
Number of subjects: 28
Study: 35662833

Group type: EXPERIMENTAL
Intervention: Masupirdine 50 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Masupirdine 100 mg
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 35662954

Group type: EXPERIMENTAL
Intervention: Cranberry supplementation for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35663154

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) therapy
Number of subjects: 337
Study: 35663286

Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam (C/T)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 100
Study: 35663767

Group type: EXPERIMENTAL
Intervention: 7.5% urea cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic moisturizer (vehicle cream)
Number of subjects: 0
Study: 35663943

Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 0
Study: 35664159

Group type: EXPERIMENTAL
Intervention: face-to-face ACT + mobile application (app)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: face-to-face ACT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study: 35664443

Group type: EXPERIMENTAL
Intervention: Single-dose Vi-DT (n=252)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Multidose Vi-DT (n=247)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Meningococcal conjugate vaccine
Number of subjects: 1800
Study: 35664760

Group type: EXPERIMENTAL
Intervention: supplemental home parenteral nutrition (sHPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-sHPN (best practice nutritional care)
Number of subjects: 0
Study: 35664765

Group type: EXPERIMENTAL
Intervention: HSPPC-96 vaccination
Number of subjects: 19
Study: 35664997

Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M™ (delayed dosing regimen)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 32
Study: 35665323

Group type: EXPERIMENTAL
Intervention: Electric impedance tomography (EIT) observation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) recruitment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: EIT observation
Number of subjects: 2
Study: 35665739

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of autologous total IgG (50 mg, 8 injections over 4 weeks)
Number of subjects: 13
Study: 35665826

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: Socio-environmental condition
Number of subjects: 1647
Study: 35666066

Group type: EXPERIMENTAL
Intervention: Low haemoglobin levels
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Higher haemoglobin levels (future investigation)
Number of subjects: 871
Study: 35666146

Group type: EXPERIMENTAL
Intervention: Higher prolactin levels at baseline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lower circulating prolactin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Decreasing prolactin quartiles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Women who developed future T2D
Number of subjects: 200
Study: 35666490

Group type: EXPERIMENTAL
Intervention: Prediction model based on the International Standards for Neurological Classification of Spinal Cord Injury total motor score collected within 40 days from injury.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bowel outcome one year after SCI derived from the SCIM item 7 scores.
Number of subjects: 142
Study: 35666538

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 99
Study: 35666728

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bronchodilators
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Length of hospitalization (LOH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PES3 score
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Age <3 months
Number of subjects: 75
Study: 35666882

Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention (8, 60-minute visits over 6 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: In-person rehabilitation intervention (8, 60-minute visits over 6 weeks)
Number of subjects: 73
Study: 35666951

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35667016

Group type: EXPERIMENTAL
Intervention: Befovacimab 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Befovacimab 225 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Befovacimab 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Befovacimab (all doses)
Number of subjects: 24
Study: 35667174

Group type: EXPERIMENTAL
Intervention: Wounds healing by secondary intention
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Significant bacterial colonisation identified on bacterial fluorescence imaging
Number of subjects: 55
Study: 35667271

Group type: EXPERIMENTAL
Intervention: Nutritional Quality Improvement Program (QIP) including education, dietary counseling, and oral nutritional supplements (ONS) for daily intake over 60 days.
Number of subjects: 618
Study: 35667399

Group type: EXPERIMENTAL
Intervention: Telehealth physical therapy (PT)
Number of subjects: 126
Study: 35667558

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine or mRNA-1273 vaccine, administered in two or three doses
Number of subjects: 138
Study: 35667724

Group type: EXPERIMENTAL
Intervention: Remote speech data collection using a smartphone app
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Remote self-administered speech tasks
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Speech tasks measuring executive control and voice quality
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Acoustic features analysis (mel-frequency cepstrum coefficients, formant frequencies, intensity, loudness)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Text-based features analysis (number of words, noun and pronoun rate, idea density)
Number of subjects: 225
Study: 35667792

Group type: EXPERIMENTAL
Intervention: Alarmin (double-stranded RNA [dsRNA])-activated Toll-like receptor signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Host-microbe interaction-related immune pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutically modulating immune signaling
Number of subjects: 0
Study: 35667900

Group type: EXPERIMENTAL
Intervention: MTX-Persistent
Number of subjects: 671

Group type: COMPARATOR
Intervention: MTX-Discontinued
Number of subjects: 671
Study: 35668120

Group type: EXPERIMENTAL
Intervention: High-SFA diet (18%TE SFAs, 16%TE UFAs)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low-SFA diet (10%TE SFAs, 24%TE UFAs)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dietary patterns analysis
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid fatty acid (PL-FA) profiles analysis
Number of subjects: 109
Study: 35668129

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 10
Study: 35668167

Group type: EXPERIMENTAL
Intervention: Smoking mothers (nicotine exposure)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonsmoking mothers (control)
Number of subjects: 64
Study: 35668295

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 1000000
Study: 35668388

Group type: EXPERIMENTAL
Intervention: Seminal miR19a levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Seminal miR19b levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Seminal miR34c levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Seminal miR133b levels
Number of subjects: 160
Study: 35668470

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing of 9 cases with unexplained primary iron overload
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sanger sequencing of UBE2O and PCSK7 genes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: In vitro siRNA interference of UBE2O and PCSK7
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adenovirus generation of UBE2O p.K689R in cell lines
Number of subjects: 27
Study: 35668496

Group type: EXPERIMENTAL
Intervention: TyG index T3 (7.77 ≤ TyG index ≤ 10.82)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: TyG index in patients with DM
Number of subjects: 731
Study: 35668498

Group type: EXPERIMENTAL
Intervention: Kinesiophobia assessment using Tampa Scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lumbar endurance assessment using Soren's lumbar extensor test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Position sense assessment using lumbar repositioning test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pain intensity assessment using visual analog scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Functional ability assessment using Patient-specific Functional Scale
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (asymptomatic individuals)
Number of subjects: 200
Study: 35668702

Group type: EXPERIMENTAL
Intervention: RSV-LRTI episodes
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Incidence rates of first episode of RSV-LRTI
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: RSV detection
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Co-detection of other viruses
Number of subjects: 2401
Study: 35668874

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0
Study: 35669046

Group type: EXPERIMENTAL
Intervention: Whole-food diet based on the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 44
Study: 35669047

Group type: EXPERIMENTAL
Intervention: Complementary feeding social and behavior change communication (SBCC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 35669271

Group type: EXPERIMENTAL
Intervention: Amisulpride + memantine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Amisulpride + placebo
Number of subjects: 36
Study: 35669398

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (10 mg/kg/day for 3 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous immunoglobulins (IVIG) (2 g/kg as a single dose)
Number of subjects: 80
Study: 35669474

Group type: EXPERIMENTAL
Intervention: Podocan levels on admission
Number of subjects: 815
Study: 35669478

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography and 3D printing guidance
Number of subjects: 166

Group type: COMPARATOR
Intervention: Transthoracic echocardiography guidance
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Local anesthesia for percutaneous procedures
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: General anesthesia for transapical procedures
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography and 3D printing
Number of subjects: 166
Study: 35669484

Group type: EXPERIMENTAL
Intervention: 9-month intervention combined with usual oncology care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 0
Study: 35669489

Group type: EXPERIMENTAL
Intervention: Tb-ERA test
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 35670217

Group type: EXPERIMENTAL
Intervention: BNP (B-type NP)
Number of subjects: 2465

Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal pro-B-type NP)
Number of subjects: 2465

Group type: EXPERIMENTAL
Intervention: MR-proANP (midregional pro-atrial NP)
Number of subjects: 2465

Group type: EXPERIMENTAL
Intervention: BNP and NT-proBNP
Number of subjects: 2465

Group type: COMPARATOR
Intervention: MR-proANP
Number of subjects: 2465
Study: 35670263

Group type: EXPERIMENTAL
Intervention: Preoperative functional urethral length (FUL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preoperative maximum urethral closure pressure (MUCP)
Number of subjects: 43
Study: 35670715

Group type: EXPERIMENTAL
Intervention: Fluorine 18-labeled sodium fluoride (NaF) PET imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study: 35671038

Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 4 weeks
Number of subjects: 2561
Study: 35671073

Group type: EXPERIMENTAL
Intervention: Prototype diagnostic decision support system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care visits
Number of subjects: 0
Study: 35671108

Group type: EXPERIMENTAL
Intervention: Guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200 mg i.v.) on day 5, every 21 days
Number of subjects: 35
Study: 35671201

Group type: EXPERIMENTAL
Intervention: Tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tremelimumab 1 mg/kg (Q4W for 4 doses) plus durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fixed-dose tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg (Q4W/Q12W)
Number of subjects: 65